Article in Cancer discovery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
52 authors.
Kai YuDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0009-0006-3070-1598
Jianfeng ChenDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0003-3750-1207
Yu-Yi ChuDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0003-3780-3061
Sajith NairDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0009-0009-6130-8897
Emanuele CrupiDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-3379-2644
Elshad HasanovDepartment of Internal Medicine, Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.ORCID 0000-0002-7195-0842
Ying MeiDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-8014-9715
Xueshuai HanDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-9931-0150
Yang LiuDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0009-0006-4321-0878
Yunhe LiuDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-2120-952X
Guangsheng PeiDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0003-1804-7598
Fuduan PengDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0003-4068-530X
Jianlong LiaoDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0009-0000-7980-026X
Enyu DaiDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0001-5836-0277
Tian ChuDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-6840-0452
Kyung Serk ChoDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-0996-8240
Jiahui JiangDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0009-0006-7869-2408
Xinmiao YanDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-9749-1621
Yibo DaiDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0009-0007-8023-4665
Jun WangDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-5955-6543
Baifeng ZhangDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0003-1966-2285
Giannicola GenoveseDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0003-1392-9954
Nagireddy PutluriDepartment of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas.ORCID 0000-0003-4488-7400
Livia EberlinDivision of Surgical Oncology, Baylor College of Medicine, Houston, Texas.ORCID 0000-0002-3885-3215
Liuqing YangDepartment of Molecular Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-6518-474X
Chunru LinDepartment of Molecular Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-6473-8229
Lawrence N KwongDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0001-8370-1432
Diana ShamsutdinovaDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0003-1057-1731
Khalida M WaniDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-2383-3908
Bogdan A CzerniakDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-8289-9173
Wendong YuDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0001-8958-6762
Jianping ZhaoDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-1855-3039
Charles C GuoDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0003-2182-3287
Donna HanselDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0001-7860-4881
Curtis PettawayDepartment of Urology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0003-1697-1840
Louis PistersDepartment of Urology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-9226-6062
Kelly BreeDepartment of Urology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0003-4532-7763
Neema NavaiDepartment of Urology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0001-8457-3786
Byron H LeeDepartment of Urology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-8755-9688
Ashish M KamatDepartment of Urology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0003-3546-9928
Padmanee SharmaDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0003-4658-055X
Paul CornDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-4106-6335
Cindy Y JiangDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-2459-1875
Amishi Y ShahDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-9007-0621
Omar AlhalabiDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-9658-2206
Pavlos MsaouelDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0001-6505-8308
Arlene O Siefker-RadtkeDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-6328-9599
Christopher J LogothetisDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-6365-1711
Matthew T CampbellDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0003-1915-4491
Alexander J LazarDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-6395-4499
Jianjun GaoDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0001-6138-4472
Linghua WangDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0001-9380-0266
Funding
Center for Gastric Pre-Cancer Atlas of Multidimensional Evolution in 3D (GAME3D)U01CA294518 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Paul F Mansfield, Linghua Wang · 2024 to 2026
$5.4M
Tumor cell lineage diversity and composition in gastric cancer progression and therapy resistanceR01CA266280 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Pawel K. Mazur, Linghua Wang · 2022 to 2026
$3.2M
Investigation of the role of epithelial-mesenchymal plasticity in renal cell carcinomaR01CA258226 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI GENOVESE, GIANNICOLA · 2021 to 2025
$2.9M
Effective combination therapy for MTAP-deficient bladder carcinoma by targeting metabolic vulnerability and modulating tumor immune microenvironmentR01CA254988 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI GAO, JIANJUN · 2021 to 2025
$2.6M
Decoding tumor metabolic and immunologic interactions driving racial disparity in African American patients with bladder cancer.R01CA282282 · NCI · BAYLOR COLLEGE OF MEDICINE · PI Jianjun Gao, Nagireddy Putluri · 2023 to 2026
$2.5M
Macrophages as modulators of T cell function and therapeutic response in clear cell renal cell carcinomaR01CA258886 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI HAKIMI, ABRAHAM ARI · 2021 to 2025
$2.4M
Elucidating T Cell Ferroptosis in Renal Medullary Carcinoma: 3D Genome Architecture Rewiring and Therapeutic AlleviationR01CA285454 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Wenbo Li, Pavlos Msaouel · 2024 to 2026
$2.0M
Mechanisms of Hyperprogression to Immunotherapy in SMARCB1-Deficient Renal MalignanciesR37CA288448 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Pavlos Msaouel · 2024 to 2026
$2.0M
Molecular Mechanisms of Bladder Cancer ImmunometabolismR01CA269489 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Jianjun Gao, Liuqing Yang · 2023 to 2026
$2.0M
Break Through Cancer (BTC)Cancer Prevention and Research Institute of Texas (CPRIT) RP200385Cancer Prevention and Research Institute of Texas (CPRIT) RP260133Center for Cancer Research (CCR) R01CA254988Center for Cancer Research (CCR) R01CA258226Center for Cancer Research (CCR) R01CA258886Center for Cancer Research (CCR) R01CA266280Center for Cancer Research (CCR) R01CA269489Center for Cancer Research (CCR) R01CA282282Center for Cancer Research (CCR) R01CA285454Center for Cancer Research (CCR) R37CA288448Center for Cancer Research (CCR) U01CA294518Gateway for Cancer Research (GCR)Kidney Cancer Association (KCA) Advanced Discovery AwardNational Cancer Institute (NCI) T32217789NCI NIH HHS R01 CA254988NCI NIH HHS R01 CA258226NCI NIH HHS R01 CA258886NCI NIH HHS R01 CA266280NCI NIH HHS R01 CA269489NCI NIH HHS R01 CA282282NCI NIH HHS R01 CA285454NCI NIH HHS R37 CA288448NCI NIH HHS U01 CA294518University of Texas MD Anderson Cancer Center (MD Anderson)U.S. Department of Defense (DOD) HT942525-1-0047U.S. Department of Defense (DOD) KC240237P1U.S. Department of Defense (DOD) RA230062
6 · The paper itself
Abstract
Muscle-invasive bladder cancer (MIBC) is clinically heterogeneous, and current molecular subtyping does not capture the spatial organization of tumor states and microenvironmental context. In this study, we construct a spatial atlas of MIBC by integrating spatial transcriptomics from 22 tumors with matched bulk RNA and whole-exome sequencing data. We identify a continuous, spatially organized luminal-to-basal axis within individual tumors that is associated with greater chromosomal instability and transcriptional plasticity. Luminal tumor cores are enriched for FGFR3 and NECTIN4, whereas basal-like states localize toward invasive margins and are associated with elevated EGFR signaling, epithelial-mesenchymal transition, genomic instability, immune infiltration, and greater chemotherapy sensitivity. Spatial analyses further reveal lineage- and location-associated differences in tertiary lymphoid structure states. Pan-cohort analyses across more than 3,000 tumors confirm conserved FGFR3-EGFR lineage exclusivity and associated immune programs. Together, these findings define a spatial framework for understanding lineage states, immune architecture, and therapeutic vulnerabilities in MIBC. SIGNIFICANCE: MIBC is clinically heterogeneous, yet current classification lacks spatial context for therapeutic guidance. This study establishes a spatial framework linking luminal and basal lineage states to distinct immune phenotypes and therapeutic vulnerabilities, providing a foundation for biomarker development and more precise, spatially informed, lineage-guided treatment strategies.
Indexed as
Urinary Bladder NeoplasmsHumansReceptor, Fibroblast Growth Factor, Type 3Spatial TranscriptomicsTumor MicroenvironmentFGFR3 protein, humanReceptor, Fibroblast Growth Factor, Type 3
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
A Spatial Atlas of Muscle-Invasive Bladder Cancer Reveals Lineage-Specific Vulnerabilities and Immune Architecture. · full record | OpenQuestion